 In this study, the researchers analyzed the prevalence of BRAF mutations in Korean patients with non-small cell lung cancer, NSCLC. They found that only 1.3% of the patients tested positive for BRAF mutations, which were mostly V600E mutations. Additionally, they observed that the presence of micropapillary components in the tumor was associated with BRAF mutations. This article was authored by Hyoyoung-on, Chung-hwan Lee, Min-ki Lee, and others.